Minnow Medical, Inc, headquartered in San Diego, California, is a developmental stage company in its fifth year of operations. Minnow Medical is establishing its first products in the treatment of peripheral arterial disease. The company plans on leveraging its broadly applicable technology throughout the cardiovascular system.

Minnow Medical's extensive team experience in cardiovascular biology, radiofrequency energy, and tissue biology, combined with scientific expertise in atherosclerosis, has resulted in the development of a different approach to peripheral arterial disease through the Minnow Medical Peripheral Vascular System™.

Atherosclerosis is a disease affecting the arteries of the body that is commonly referred to as “hardening of the arteries.” It is caused by a buildup of plaque, or tissue that blocks the opening of the artery. Most endovascular medical devices force mechanical changes only to diseased arteries, treating both healthy and diseased tissue indiscriminately. Available today are devices that tear, burn, or freeze the artery wall in order to reduce plaque deposits. Although acutely effective, long-term blood flow remains an unmet clinical need.

Minnow Medical's solution to the problem of treating arterial disease is a proprietary system which incorporates a catheter and energy based technology which delivers precisely-controlled, non-ablative, low-powered radiofrequency (RF) energy, which triggers biologic responses in diseased peripheral arteries that open stenoses and reduce plaque volume, potentially resulting in a permanently reshaped artery.

The Minnow Medical Peripheral Vascular System, through a combination of radiofrequency and mechanical energy, accomplishes this stenosis dilation and plaque reduction in peripheral arteries via hyperthermia and mild pressure, respectively.

Minnow Medical's Peripheral Vascular System is not for sale at this time. The claims for this device made on this website describe the expected clinical performance of the device and have not yet been confirmed through clinical trials.